Posted by Michael Wonder on 04 Sep 2018
Vertex announces reimbursement agreement in Australia for Orkambi (lumacaftor/ivacaftor) for people with cystic fibrosis ages six years and older with two copies of the F508del mutation
3 September 2018 - Approximately 1,300 patients in Australia join the thousands of patients worldwide who already have access to lumacaftor/ivacaftor.
Vertex Pharmaceuticals announces finalisation of an agreement with the Australian Government that allows for reimbursement of Orkambi (lumacaftor/ivacaftor) for people ages six and over with cystic fibrosis (CF) who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene. This agreement means lumacaftor/ivacaftor will be listed on the Pharmaceutical Benefits Scheme from 1 October and follows a positive recommendation from the Pharmaceutical Benefits Advisory Committee.
A pathway to access for future Vertex CF medicine, tezacaftor/ivacaftor, has been established as part of this process.
